3.0.0
8454
2023-09-05T17:28:35Z
2023-09-05T17:28:35Z
House
HR
2022-07-21
117
[Congressional Record Volume 168, Number 121 (Thursday, July 21, 2022)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. BLUMENAUER:H.R. 8454.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 3 of the U.S. Constitution[Page H7066]
- hsju00
Judiciary Committee
House
Standing
  - Referred to
2022-07-21T13:00:20Z
- hsif00
Energy and Commerce Committee
House
Standing
  - Referred to
2022-07-21T13:00:15Z

- Cannabidiol and Marihuana Research Expansion Act
117
253
S
2022-03-28
Held at the desk.
14:06:52
  - Related bill
CRS
- 2022-12-02
Became Public Law No: 117-215.
President
E40000
9
Library of Congress
- 2022-12-02
Became Public Law No: 117-215.
BecameLaw
36000
9
Library of Congress
- 2022-12-02
Signed by President.
President
E30000
9
Library of Congress
- 2022-12-02
Signed by President.
BecameLaw
36000
9
Library of Congress
- 2022-11-29
Presented to President.
Floor
E20000
2
House floor actions
- 2022-11-29
Presented to President.
President
28000
9
Library of Congress
- 2022-11-17
Senate
Message on Senate action sent to the House.
Floor
- 2022-11-16
Senate
Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
Floor
- 2022-11-16
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
Floor
17000
9
Library of Congress
- 2022-07-27
Senate
Received in the Senate, read twice.
IntroReferral
- 2022-07-26
20:43:54
Motion to reconsider laid on the table Agreed to without objection.
Floor
H38310
2
House floor actions
- 2022-07-26
20:43:53
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
Floor
H37300
2
House floor actions
392
https://clerk.house.gov/evs/2022/roll392.xml
House
117
2022-07-27T00:43:53Z
2
- 2022-07-26
20:43:53
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392).(text: CR H7120-7122)
Floor
8000
9
Library of Congress
392
https://clerk.house.gov/evs/2022/roll392.xml
House
117
2022-07-27T00:43:53Z
2
- 2022-07-26
20:34:11
Considered as unfinished business. (consideration: CR H7145-7146)
Floor
H30000
2
House floor actions
- 2022-07-26
17:01:56
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Floor
H37220
2
House floor actions
- 2022-07-26
16:48:55
DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
Floor
H8D000
2
House floor actions
- 2022-07-26
16:48:54
Considered under suspension of the rules. (consideration: CR H7120-7124)
Floor
H30000
2
House floor actions
- 2022-07-26
16:48:42
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Floor
H30300
2
House floor actions
- 2022-07-21
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2
House floor actions
  - hsju00
Judiciary Committee
- 2022-07-21
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2
House floor actions
  - hsif00
Energy and Commerce Committee
- 2022-07-21
Introduced in House
IntroReferral
Intro-H
9
Library of Congress
- 2022-07-21
Introduced in House
IntroReferral
1000
9
Library of Congress
- B000574
Rep. Blumenauer, Earl [D-OR-3]
EARL
BLUMENAUER
D
OR
3
N
- H001052
Rep. Harris, Andy [R-MD-1]
Andy
Harris
R
MD
1
2022-07-21
True
- G000568
Rep. Griffith, H. Morgan [R-VA-9]
H.
Griffith
R
VA
Morgan
9
2022-07-21
True
- J000295
Rep. Joyce, David P. [R-OH-14]
David
Joyce
R
OH
P.
14
2022-07-21
True
- N000147
Del. Norton, Eleanor Holmes [D-DC-At Large]
ELEANOR
NORTON
D
DC
HOLMES
0
2022-07-21
True
- M000194
Rep. Mace, Nancy [R-SC-1]
Nancy
Mace
R
SC
1
2022-07-21
True
- P000593
Rep. Perlmutter, Ed [D-CO-7]
Ed
Perlmutter
D
CO
7
2022-07-21
True
- P000614
Rep. Pappas, Chris [D-NH-1]
Chris
Pappas
D
NH
1
2022-07-22
False
- L000551
Rep. Lee, Barbara [D-CA-13]
BARBARA
LEE
D
CA
13
2022-07-22
False
- D000624
Rep. Dingell, Debbie [D-MI-12]
Debbie
Dingell
D
MI
12
2022-07-22
False
- C001068
Rep. Cohen, Steve [D-TN-9]
Steve
Cohen
D
TN
9
2022-07-22
False
- Public Law
117-215
Crime and Law Enforcement
- Alternative treatments
- Congressional oversight
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Drug trafficking and controlled substances
- Drug, alcohol, tobacco use
- Health personnel
- Licensing and registrations
- Medical research
- Public-private cooperation
- Research administration and funding
Crime and Law Enforcement
00
2022-07-21
Introduced in House
2023-02-24T20:04:22Z
Medical Marijuana and Cannabidiol Research Expansion Act
This bill establishes a new, separate registration process to facilitate research on marijuana.
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
Finally, the bill includes various other provisions, including provisions that
- require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
- prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
- allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
- require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
53
2022-07-26
Passed House
2023-02-24T20:06:18Z
Medical Marijuana and Cannabidiol Research Expansion Act
This bill establishes a new, separate registration process to facilitate research on marijuana.
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
Finally, the bill includes various other provisions, including provisions that
- require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
- prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
- allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
- require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
55
2022-11-16
Passed Senate
2023-02-24T20:07:44Z
Medical Marijuana and Cannabidiol Research Expansion Act
This bill establishes a new, separate registration process to facilitate research on marijuana.
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
Finally, the bill includes various other provisions, including provisions that
- require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
- prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
- allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
- require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
49
2022-12-02
Public Law
2023-02-24T20:09:22Z
Medical Marijuana and Cannabidiol Research Expansion Act
This act establishes a new, separate registration process to facilitate research on marijuana.
Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
Finally, the act includes various other provisions, including provisions that
- require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
- prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
- allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
- require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.

Medical Marijuana and Cannabidiol Research Expansion Act
- Display Title

Medical Marijuana and Cannabidiol Research Expansion Act
- Short Titles as Enacted

Medical Marijuana and Cannabidiol Research Expansion Act
- Short Titles as Passed Senate

Medical Marijuana and Cannabidiol Research Expansion Act
S
Senate
- Official Title as Introduced

To expand research on cannabidiol and marijuana, and for other purposes.
Introduced in House
IH
- Short Title(s) as Passed House

Medical Marijuana and Cannabidiol Research Expansion Act
H
House
Engrossed in House
EH
- Short Title(s) as Introduced

Medical Marijuana and Cannabidiol Research Expansion Act
Introduced in House
IH
- Enrolled Bill
  - https://www.govinfo.gov/content/pkg/BILLS-117hr8454enr/xml/BILLS-117hr8454enr.xml
- Received in Senate
2022-07-27T04:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-117hr8454rds/xml/BILLS-117hr8454rds.xml
- Engrossed in House
2022-07-26T04:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-117hr8454eh/xml/BILLS-117hr8454eh.xml
- Introduced in House
2022-07-21T04:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-117hr8454ih/xml/BILLS-117hr8454ih.xml
- 2022-12-03T04:59:59Z
  - https://www.govinfo.gov/content/pkg/PLAW-117publ215/uslm/PLAW-117publ215.xml
Public Law
2022-12-02
Became Public Law No: 117-215.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.